Different treatment schedules for liver scarring from schistosomiasis
Part of Digestive system, Infections clinical trials.
This trial tests whether giving treatment for schistosomiasis (a parasite infection) more often helps reduce liver scarring (fibrosis). It compares different schedules of medication to see which works best and may improve liver health.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have an active schistosomiasis infection (a parasite infection) confirmed by a urine test.
- You have liver scarring (fibrosis) caused by schistosomiasis, but not advanced-stage liver disease.
- You are between 15 and 40 years old.
- You are generally healthy apart from the schistosomiasis infection.
- You are not pregnant.
- You do not have other causes of liver damage, such as hepatitis B or C or alcoholic cirrhosis.
- You have no history of bleeding in the upper digestive tract.
- You do not have certain infections caused by the same parasite (neurocysticercosis or ocular cysticercosis).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial looks at how active a long-term schistosomiasis infection is in travelers and migrants. It aims to better understand the infection to help guide treatment.
This study looks at how well the right side of your heart works with the blood vessels in your lungs. It focuses on people who have both schistosomiasis (a parasitic infection) and high blood pressure in the lungs, to help doctors better understand and treat this condition.
This study looks at whether a more precise DNA-based test can better find and confirm schistosomiasis (a parasite infection) compared to standard methods. It may help you get a clearer diagnosis and more targeted care.
This study tests a new medicine called arpraziquantel to treat schistosomiasis (a disease from parasites in water) in young children aged 2 to 5. It aims to see if giving this treatment in communities where the disease is common is safe and helpful.
This study tests whether a new drug called AZD2389 is safe and well-tolerated in adults with steatotic liver disease (fatty liver) that has progressed to advanced scarring. The trial aims to see if this drug might help slow or improve liver damage in people with this condition.
This study compares two treatments for liver scarring in people with overweight or related health issues. One group follows a special diet with restricted eating times, while the other takes a combination of two medications (naltrexone and bupropion). It aims to see which approach better improves liver fibrosis.
Hear when a new Schistosomiasis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.